Profile: Nabriva Therapeutics PLC (NBRV.OQ)
15 Dec 2017
Nabriva Therapeutics plc, incorporated on March 1, 2017, is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin. Lefamulin is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. Lefamulin is being evaluated in two global, registrational Phase III clinical trials in patients with moderate to severe community-acquired bacterial pneumonia (CABP).
The Company’s lefamulin is well positioned for use as a first-line empiric monotherapy for the treatment of moderate to severe CABP due to its novel mechanism of action, targeted spectrum of activity, resistance profile, achievement of substantial drug concentration in lung tissue and fluid, oral and IV formulations and a favorable tolerability profile. The Company seeks to further pursue development of lefamulin for additional indications, including the treatment of acute bacterial skin and skin structure infections (ABSSSI), and is developing a formulation of lefamulin appropriate for pediatric use. The Company owns rights to lefamulin, which are protected by composition of matter patents issued in the United States, Europe and Japan.
Nabriva Therapeutics PLC
56 Fitzwilliam Square
Company Web Links
- BRIEF-Nabriva Therapeutics reports Q3 loss per share $0.79
- BRIEF-Nabriva Therapeutics announces pricing of public offering of ordinary shares of nearly $80 mln
- Nabriva's pneumonia drug succeeds in late-stage trial, shares soar
- BRIEF-Nabriva therapeutics announces positive topline results
- BRIEF-Nabriva Therapeutics reports Q2 loss per share $0.54